Latest Insider Transactions at Emergent Bio Solutions Inc. (EBS)
This section provides a real-time view of insider transactions for Emergent Bio Solutions Inc. (EBS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Emergent BioSolutions Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Emergent BioSolutions Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 02
2022
|
Keith Katkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,595
+50.0%
|
-
|
Mar 01
2022
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
25,377
+34.56%
|
-
|
Mar 01
2022
|
Katherine Strei EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,250
+23.08%
|
-
|
Mar 01
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+22.61%
|
-
|
Mar 01
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+23.78%
|
-
|
Mar 01
2022
|
Adam Havey EVP, Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
50,145
+24.44%
|
-
|
Mar 01
2022
|
Robert Kramer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
89,415
+16.59%
|
-
|
Feb 28
2022
|
Katherine Strei EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-0.84%
|
$21,879
$39.64 P/Share
|
Feb 28
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
764
-0.83%
|
$29,796
$39.64 P/Share
|
Feb 28
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
818
-0.95%
|
$31,902
$39.64 P/Share
|
Feb 28
2022
|
Adam Havey EVP, Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
739
-0.85%
|
$28,821
$39.64 P/Share
|
Feb 28
2022
|
Robert Kramer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,715
-0.69%
|
$66,885
$39.64 P/Share
|
Feb 24
2022
|
Adam Havey EVP, Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
828
-2.2%
|
$34,776
$42.47 P/Share
|
Feb 24
2022
|
Robert Kramer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-1.26%
|
$85,428
$42.47 P/Share
|
Feb 24
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
983
-2.52%
|
$41,286
$42.47 P/Share
|
Feb 24
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
857
-1.94%
|
$35,994
$42.47 P/Share
|
Feb 24
2022
|
Katherine Strei EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
590
-1.92%
|
$24,780
$42.47 P/Share
|
Feb 23
2022
|
Adam Havey EVP, Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
424
-1.11%
|
$17,808
$42.23 P/Share
|
Feb 23
2022
|
Robert Kramer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,419
-0.87%
|
$59,598
$42.23 P/Share
|
Feb 23
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
516
-1.31%
|
$21,672
$42.23 P/Share
|
Feb 23
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
442
-0.99%
|
$18,564
$42.23 P/Share
|
Feb 23
2022
|
Katherine Strei EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
344
-1.1%
|
$14,448
$42.23 P/Share
|
Feb 22
2022
|
Katherine Strei EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,616
-4.93%
|
$67,872
$42.23 P/Share
|
Feb 22
2022
|
Katherine Strei EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,258
+3.7%
|
-
|
Feb 22
2022
|
Adam Havey EVP, Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,980
-4.95%
|
$83,160
$42.23 P/Share
|
Feb 22
2022
|
Adam Havey EVP, Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+4.39%
|
-
|
Feb 22
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,084
-4.47%
|
$87,528
$42.23 P/Share
|
Feb 22
2022
|
Atul Saran EVP, Chief Strat & Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+3.79%
|
-
|
Feb 22
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,298
-5.5%
|
$96,516
$42.23 P/Share
|
Feb 22
2022
|
Richard S Lindahl EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+4.21%
|
-
|
Feb 22
2022
|
Robert Kramer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,595
-2.75%
|
$192,990
$42.23 P/Share
|
Feb 22
2022
|
Robert Kramer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,264
+2.49%
|
-
|
Dec 03
2021
|
Fuad El Hibri Director |
BUY
Other acquisition or disposition
|
Indirect |
3,500,008
+50.0%
|
-
|
Nov 15
2021
|
Richard S Lindahl EVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+6.99%
|
$111,000
$37.46 P/Share
|
May 25
2021
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
3,139
-17.92%
|
$175,784
$56.48 P/Share
|
May 20
2021
|
Jerome M Hauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+24.83%
|
-
|
May 20
2021
|
Marvin L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+36.74%
|
-
|
May 20
2021
|
George A Joulwan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+13.65%
|
-
|
May 20
2021
|
Ronald Richard Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+27.43%
|
-
|
May 20
2021
|
Zsolt Harsanyi Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+14.52%
|
-
|
May 20
2021
|
Kathryn C Zoon Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+22.3%
|
-
|
May 20
2021
|
Louis W Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,027
+10.05%
|
-
|
May 10
2021
|
Louis W Sullivan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,118
-7.24%
|
$190,198
$61.62 P/Share
|
May 10
2021
|
Louis W Sullivan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,305
+19.31%
|
$185,490
$18.64 P/Share
|
May 08
2021
|
Robert Kramer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
94
-0.06%
|
$5,734
$61.62 P/Share
|
May 08
2021
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,054
-2.78%
|
$64,294
$61.62 P/Share
|
May 07
2021
|
Karen L. Smith EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-2.5%
|
$18,300
$60.85 P/Share
|
Mar 31
2021
|
Sean Kirk EVP, Manufacturing & Tech Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
159
-0.89%
|
-
|
Mar 04
2021
|
Sue Bailey Director |
SELL
Open market or private sale
|
Direct |
8,168
-25.06%
|
$751,456
$92.37 P/Share
|
Mar 01
2021
|
Adam Havey EVP, Business Operations |
SELL
Open market or private sale
|
Direct |
37,279
-32.75%
|
$3,690,621
$99.32 P/Share
|